Suleman Bhana, MD
@drbhana.bsky.social
Rheumatologist and tech nerd. OG Rheum Twitter alumni and former podcaster. Work in biopharma. Views are my own. #RheumSky
Reposted by Suleman Bhana, MD
I’m encouraged by the so-far-so-good results of #CAR-T cells in human clinical trials for autoimmune diseases! Side note: If you’re interested in a clever twist of CAR-T, called “CAART,” that could reduce global immunosuppression, check out Dr. Aimee Payne’s work @columbiauniversity.bsky.social
Living Drugs for the Skin, and Beyond
In the lab, Aimee Payne, Columbia’s new chair of dermatology, is transforming cells into living drugs for autoimmune diseases of the skin.
www.cuimc.columbia.edu
February 15, 2025 at 6:08 PM
I’m encouraged by the so-far-so-good results of #CAR-T cells in human clinical trials for autoimmune diseases! Side note: If you’re interested in a clever twist of CAR-T, called “CAART,” that could reduce global immunosuppression, check out Dr. Aimee Payne’s work @columbiauniversity.bsky.social
Reposted by Suleman Bhana, MD
⚠️ Cytokine Release Syndrome is a serious side effect of #CAR-T cell therapies. This article examines the pathways driving cytokine production in T cells during #immunotherapy: 🔗 doi.org/10.1093/imma... (6/8)
Regulation of temporal cytokine production by co-stimulation receptors in TCR-T cells is lost in CAR-T cells
Abstract. CD8+ T cells contribute to immune responses by producing cytokines when their T-cell receptors (TCRs) recognise peptide antigens on major-histoco
doi.org
February 4, 2025 at 11:25 AM
⚠️ Cytokine Release Syndrome is a serious side effect of #CAR-T cell therapies. This article examines the pathways driving cytokine production in T cells during #immunotherapy: 🔗 doi.org/10.1093/imma... (6/8)
Reposted by Suleman Bhana, MD
Finally a minimum of 5 trials of orflorglipron reading out in 2025 with the first trial to readout in April or May. As noted it's an oral GLP-1 non peptide drug. It's easily mass produced, requires no special dosing or refrigeration. Lilly expects worldwide launch January 2026 for obesity & DM2
February 6, 2025 at 5:57 PM
Finally a minimum of 5 trials of orflorglipron reading out in 2025 with the first trial to readout in April or May. As noted it's an oral GLP-1 non peptide drug. It's easily mass produced, requires no special dosing or refrigeration. Lilly expects worldwide launch January 2026 for obesity & DM2